Progress your RA Agent Drug Development with our In Vivo Preclinical Models
Utilize preclinical models with diverse mechanisms capturing key characteristic clinical and pathologic RA features to determine efficacy and response to treatment, and improve selection of your next qualified RA lead agent. Choose from the:
- collagen antibody-induced arthritis mouse model
- collagen-induced arthritis mouse model
Collagen Antibody-Induced Arthritis (CAIA) Mouse Model
RA is induced through administration of commercially available antibodies targeting Type II collagen and results in rapid onset of disease.
Collagen-Induced Arthritis (CIA) Mouse Model
DBA/1 mice are immunized with Type II collagen and boosted with IFA. Peak disease occurs 8-15 days post IFA boost.
- Swollen joint count
- Assessment of inflammatory mediators/cytokines
- Histopathological assessment
CAIA Model + Dexamethasone
Representative Forepaw Histology Photomicrographs
Non-lesioned paw. A distal phalangeal bone (P), carpal bone (C), and proximal interphalangeal joint (J) are indicated.
Marked inflammation (*) of the intra- and peri-articular tissues, affecting the interphalangeal joints (phalangeal bone, P) and carpal (C) joints is noted. Cartilage damage (black arrows), bone resorption (black arrowheads), pannus (blue arrowheads), and periosteal new bone (NB) are indicated.
Forepaw lacks lesions associated with arthritis. Interphalangeal joint (J), proximal phalangeal bone (P), and carpal bone (C) are indicated.